Cancer Research Meeting Calendar  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedlos, F.
Right arrow Articles by Springer, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedlos, F.
Right arrow Articles by Springer, C. J.
[Cancer Research 62, 1724-1729, March 15, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Three New Prodrugs for Suicide Gene Therapy Using Carboxypeptidase G2 Elicit Bystander Efficacy in Two Xenograft Models

Frank Friedlos, Lawrence Davies, Ian Scanlon, Lesley M. Ogilvie, Janet Martin, Stephen M. Stribbling, Robert A. Spooner, Ion Niculescu-Duvaz, Richard Marais and Caroline J. Springer1

Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG United Kingdom [F. F., L. D., I. S., L. M. O., J. M., S. M. S., R. A. S., I. N-D., C. J. S.], and Cancer Research Campaign Centre for Cell and Molecular Biology, Institute of Cancer Research, London, SW3 6JB United Kingdom [R. A. S., R. M.]

Three new prodrugs, {prodrug 1: 4-[bis(2-iodoethyl)amino]-phenyloxycarbonyl-L-glutamic acid; prodrug 2: 3-fluoro-4-[bis(2-chlorethyl)amino]benzoyl-L-glutamic acid; and prodrug 3: 3,5-difluoro-4-[bis(2-iodoethyl)amino]benzoyl-L-glutamic acid} have been assessed for use with a mutant of carboxypeptidase G2 (CPG2, glutamate carboxypeptidase, EC 3.4.17.11,) engineered to be tethered to the outer tumor cell surface (stCPG2(Q)3) as the activating enzyme in suicide gene therapy systems. All three of the prodrugs produce much greater cytotoxicity differentials between stCPG2(Q)3- and control ß-galactosidase (ß-gal)-expressing breast carcinoma MDA MB 361 and colon carcinoma WiDr cells (70- to 450-fold) than was previously observed (19- to 27-fold) with 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). Prodrug 1 is the most effective antitumor agent in xenografts in mice inoculated with 100% stCPG2(Q)3-expressing MDA MB 361 cells, whereas prodrugs 2 and 3 are most effective when the percentage of stCPG2(Q)3-expressing cells is 50% or 10%. In nude mice bearing xenografts arising from inocula of 100% stCPG2(Q)3-expressing WiDr cells, prodrug 2 is the most effective antitumor agent. All three of the prodrugs produced histological evidence of substantial bystander cell killing in WiDr xenografts in which only 10% or 50% of the cells inoculated were expressing stCPG2(Q)3. We conclude that all three of the prodrugs are more effective therapeutically with stCPG2(Q)3 than is the previously described prodrug CMDA and, also, that the optimal choice of prodrug varies among different tumor types and that prodrugs, optimized for their bystander effect, are effective when only low percentages of cells in a tumor express CPG2.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
F. Friedlos, P. Lehouritis, L. Ogilvie, D. Hedley, L. Davies, D. Bermudes, I. King, J. Martin, R. Marais, and C. J. Springer
Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy
Clin. Cancer Res., July 1, 2008; 14(13): 4259 - 4266.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Schepelmann, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, P. Chen, R. Marais, and C. J. Springer
Suicide Gene Therapy of Human Colon Carcinoma Xenografts Using an Armed Oncolytic Adenovirus Expressing Carboxypeptidase G2
Cancer Res., May 15, 2007; 67(10): 4949 - 4955.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Schepelmann, P. Hallenbeck, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, C. Hay, L. K. Hawkins, R. Marais, et al.
Systemic Gene-Directed Enzyme Prodrug Therapy of Hepatocellular Carcinoma Using a Targeted Adenovirus Armed with Carboxypeptidase G2
Cancer Res., June 15, 2005; 65(12): 5003 - 5008.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C.-Q. Ling, B. Li, C. Zhang, D.-Z. Zhu, X.-Q. Huang, W. Gu, and S.-X. Li
Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma
Ann. Onc., January 1, 2005; 16(1): 109 - 115.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.